Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 7/20 | 0.39 |
| ▸ | JAK3 | P52333 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 5/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634249 | 0.95 | CDK9 (0.40) | JAK1JAK3JAK2CDK2CDK9 | |
| SCHEMBL14634045 | 0.90 | JAK1 (0.38) | JAK1JAK3JAK2CDK2CDK9 | |
| SCHEMBL14634057 | 0.89 | CDK2 (0.38) | JAK1JAK3JAK2CDK2CDK9 | |
| SCHEMBL14634222 | 0.89 | RIPK2 (0.43) | JAK1JAK3JAK2CDK2CDK9 | |
| SCHEMBL14633508 | 0.87 | JAK1 (0.38) | JAK1JAK3JAK2CDK2CDK9 | |
| SCHEMBL2467714 | 0.87 | JAK1 (0.40) | JAK1JAK3JAK2CDK2CDK9 | |
| SCHEMBL14634215 | 0.85 | CDK2 (0.39) | JAK1JAK3JAK2CDK2CDK9 | |
| SCHEMBL14633760 | 0.85 | CCNT1 (0.37) | JAK1JAK3JAK2CDK2CDK9 | |
| SCHEMBL14633989 | 0.85 | SYK (0.42) | JAK1JAK3JAK2CDK2CDK9 | |
| SCHEMBL14633563 | 0.85 | CDK2 (0.39) | JAK1JAK3JAK2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | JAK1 58/4885JAK3 102/4885JAK2 45/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | JAK1 93/4885JAK3 107/4885JAK2 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.